Serotonin levels in children with albinism
Part of Blood & lymphatic, Eyes & vision, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study measures blood serotonin levels in children with albinism compared to children without the condition. It aims to learn if serotonin plays a role in albinism, which could help future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For children with albinism: ages 2 to 17 years old.
- For children with albinism: being seen at the MAGEC-Necker reference center.
- For children without albinism (controls): ages 2 to 17 years old and having a blood test at Necker hospital.
- For controls: normal results from routine blood tests (CBC and CRP).
- For controls: parent or guardian does not object after receiving study information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for adults with any type of albinism. It looks at how albinism affects your everyday vision and activities through a simple questionnaire.
This study checks if a light-based device can measure bilirubin levels accurately without a blood test, by comparing it with the standard blood test. It looks at newborns of different skin colours to make sure the device works for everyone.
This study looks at immune cells in blood to better understand rare brain conditions caused by genetic changes. It may help researchers understand why symptoms happen and how the immune system is involved.
This study follows people with Bardet-Biedl syndrome (BBS) or Alström syndrome (ALMS) to spot early vision, metabolic (body chemistry/energy), and kidney problems. You may be asked to have clinical checks over time to help researchers better understand how these complications develop.
This study looks at blood samples from children (and sometimes parents) to see if certain protein patterns can help identify or better understand autism spectrum disorder. The results could support finding “biomarkers,” which are measurable signs that may guide future research or care.
This trial looks at a blood test (a “biomarker”) in children with amblyopia, a common vision development problem. It may help researchers understand what changes go along with treatment and vision improvement.
Hear when a new Oculocutaneous Albinism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.